In the past decade, Precision Medicine has significantly advanced the field of oncology by taking into account individual variability in genes, environment, and lifestyle for disease treatment and prevention.  Specifically, new technologies and biomedical informatics tools have allowed for rapid matching of targeted cancer therapies to tumors harboring specific genetic mutations or genetic biomarkers associated with drug efficacy. Recent efforts have enabled drug development against previous “undruggable” targets such as KRAS, which will further empower oncologists to more effectively treat patients.  Yet, with all of the progress and impact that Precision Oncology has had on patient outcomes, these benefits have not been available equitably, especially considering patients from underrepresented groups. 

This meeting will bring together thought leaders across the continuum of translational and clinical cancer research to highlight recent advances and progress in Precision Oncology, including targeted therapeutic development, innovations in technologies for molecular profiling, and Precision Oncology clinical trial updates.  The meeting will also address a major gap in current Precision Oncology approaches, namely lack of diversity in discovery datasets and clinical trials, as well as disparities in access to these health care innovations. We will discuss the sources and impacts of these deficiencies, and strategies to correct them. The outcomes of this meeting will improve our ability to develop and implement the most effective approaches for precision care  and accelerate clinical advances for ALL cancer patients, across diverse demographics.